Company Profile
Sangamo Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- SGMO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.07 USD (-57.54%)
Close
Last updated: June 23, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for SGMO.
Company overview
Business overview
Sangamo Therapeutics is a genomic medicine company focused on gene regulation, gene editing, and related platform approaches. Its story is built around advancing genetic medicine across multiple disease areas.
Geographic Base and Sector Classification
Sangamo is headquartered in the United States and listed on NASDAQ. It sits in genomic medicine and biotechnology.
Business Model Characteristics
The company depends on clinical progress, partner relationships, and the ability to translate gene-editing science into durable therapeutic value. Investors watch pipeline updates, alliances, and capital runway.
Position Within the Biotechnology Landscape
Sangamo occupies a foundational genomic-medicine niche within biotech. It remains catalyst-sensitive because the market wants proof that the platform can continue to convert science into assets.
Future catalysts
Sangamo’s catalysts are its gene-regulation and genomic-medicine programs, plus any partnering or clinical update that keeps the platform credible. The company still needs stronger human proof.
Recent news
- 01
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
Source: Sangamo Therapeutics, Inc.
- 02
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
Source: Sangamo Therapeutics, Inc.
- 03
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Source: Sangamo Therapeutics, Inc.
- 04
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
Source: Sangamo Therapeutics, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sangamo Therapeutics, Inc. (SGMO)?
Sangamo Therapeutics, Inc. (SGMO) most recently closed at 0.07 USD, a -57.54% move versus the previous session.
What does Sangamo Therapeutics, Inc. do?
Sangamo Therapeutics is a genomic medicine company focused on gene regulation, gene editing, and related platform approaches. Its story is built around advancing genetic medicine across multiple disease areas.
On which exchange is SGMO stock listed?
Sangamo Therapeutics, Inc. (SGMO) is associated with NASDAQ, United States, Biopharma.
What is Sangamo?
Sangamo’s catalysts are its gene-regulation and genomic-medicine programs, plus any partnering or clinical update that keeps the platform credible.
Which conditions is Sangamo Therapeutics, Inc. targeting with Sangamo?
Sangamo Therapeutics, Inc. is associated with genetic disease based on its company overview and current catalyst commentary.
How does Sangamo Therapeutics, Inc. describe recent progress with Sangamo?
Sangamo’s catalysts are its gene-regulation and genomic-medicine programs, plus any partnering or clinical update that keeps the platform credible.
What is Therapeutics?
Sangamo Therapeutics is a genomic medicine company focused on gene regulation, gene editing, and related platform approaches.
What should investors watch for with Therapeutics?
Sangamo’s catalysts are its gene-regulation and genomic-medicine programs, plus any partnering or clinical update that keeps the platform credible. The company still needs stronger human proof.